Increased immune protection of mice from TAP-negative tumor challenge by VV-B7.1+VV-TAP1-infected CMT.64 cell immunization.

C57BL/6 mice (each group, n = 10) were immunized i.p with CMT.64 cells (5×106 cells/mouse) infected overnight with VV-GFP+VV-GFP, VV-B7.1+VV-GFP, or VV-B7.1+VV-TAP1 at MOI of 3 for each VV. After a 20-day immunization, mice were challenged i.p. with live CMT.64 tumor cells (2.5×105 cells/mouse), and the time of morbidity was recorded.#Experiments ended at day 120 of CMT.64 cell challenge.*Indicated that the tested mouse groups compared with a control group (immunized with VV-GFP+VV-GFP-infected CMT.64 cells) for statistical analysis (ANOVA).